JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, J. P.
Right arrow Articles by Fleckenstein, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, J. P.
Right arrow Articles by Fleckenstein, A. E.

Vol. 300, Issue 3, 1093-1100, March 2002

Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity

J. Paul Hansen, Evan L. Riddle, Verónica Sandoval, Jeffrey M. Brown, James W. Gibb, Glen R. Hanson and Annette E. Fleckenstein

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

Administration of a high-dose regimen of methamphetamine (METH) rapidly and profoundly decreases plasmalemmal and vesicular dopamine (DA) transport in the striatum, as assessed in synaptosomes and purified vesicles, respectively. To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed. Similar to effects of METH reported previously, multiple high-dose MDMA administrations rapidly (within 1 h) decreased plasmalemmal DA uptake, as assessed ex vivo in synaptosomes prepared from treated rats. Unlike effects of multiple METH injections, this deficit was reversed completely 24 h after drug treatment. Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport. However, a role for phosphorylation was suggested because pretreatment with protein kinase C inhibitors attenuated the deficit caused by MDMA in an in vitro model system. In addition to affecting DAT function, MDMA rapidly decreased vesicular DA transport as assessed in striatal vesicles prepared from treated rats. Unlike effects of multiple METH injections reported previously, this decrease partially recovered by 24 h after drug treatment. Taken together, these results reveal several differences between effects of MDMA and previously reported METH on DAT and VMAT-2; differences that may underlie the dissimilar neurotoxic profile of these agents.

0022-3565/02/3003-1093$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
C. D Verrico, L. Lynch, M. A Fahey, A.-K. Fryer, G. M Miller, and B. K Madras
MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor
J Psychopharmacol, March 1, 2008; 22(2): 187 - 202.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
T.-K. Sang, H.-Y. Chang, G. M. Lawless, A. Ratnaparkhi, L. Mee, L. C. Ackerson, N. T. Maidment, D. E. Krantz, and G. R. Jackson
A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine
J. Neurosci., January 31, 2007; 27(5): 981 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Escubedo, C. Chipana, M. Perez-Sanchez, J. Camarasa, and D. Pubill
Methyllycaconitine Prevents Methamphetamine-Induced Effects in Mouse Striatum: Involvement of {alpha}7 Nicotinic Receptors
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 658 - 667.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. C. Jones, S. S. Lau, and T. J. Monks
Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 298 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. J. Baucum II, K. S. Rau, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism
J. Neurosci., March 31, 2004; 24(13): 3436 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors
J. Neurosci., October 1, 2002; 22(19): 8705 - 8710.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.